A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
Phase of Trial: Phase II/III
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Axitinib (Primary) ; Octreotide
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 23 Aug 2017 Trial phase has been changed from phase II to phase II\III.
- 23 Aug 2017 Planned number of patients changed from 80 to 253.
- 23 Aug 2017 Planned End Date changed from 1 Dec 2015 to 1 Oct 2020.